華檢醫療(01931.HK)指派56%員工協作凝血分析 積極抗疫
華檢醫療(01931.HK)公布,自Covid-19(新型冠狀病毒肺炎)爆發以來,集團一直依靠凝血分析的專業知識積極參與抗疫。根據內地當地機關發佈的相關數據,本月16日止,內地有2,108家醫院受指定治療Covid-19病人。其中,974家醫院(約佔46.2%)配備集團全資附屬威士達醫療設備安裝的Sysmex凝血分析儀,以進行凝血分析。
至今,公司已指派326名專業技術人員和工程師(佔集團員工人數約56%)與前線醫護團隊緊密協作,以維持凝血分析儀的高效及有效運轉,滿足因Covid-19爆發對凝血分析的龐大需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.